Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678

European Journal of Pharmacology

Volumn 601, Issue 1-3, 2008, Pages 163-170

  Deguchi, Masashi ^a   Kishino, Junji ^a   Hattori, Maki ^a   Furue, Yoko ^a   Yamamoto, Mina ^a   Mochizuki, Izumi ^a   Iguchi, Motofumi ^a   Hirano, Yosuke ^a   Hojou, Kanji ^a   Nagira, Morio ^a   Nishitani, Yoshinori ^a   Okazaki, Kenichi ^a   Yasui, Kiyoshi ^a   Arimura, Akinori ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

B cell; DHO DH; Humoral immunity; Immunoglobulin; S 2678

Indexed keywords

DIHYDROOROTATE DEHYDROGENASE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; LEFLUNOMIDE; OVALBUMIN; S 2678; TACROLIMUS; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CANDIDIASIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; WISTAR RAT;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; BIPHENYL COMPOUNDS; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYBUTYRATES; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULINS; ISOXAZOLES; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PYRIDINES;

EID: 56949092768     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.09.010     Document Type: Article

References (20)

1. Begum N.A., Izumi N., Nishikori M., Nagaoka H., Shinkura R., and Honjo T. Requirement of non-canonical activity of uracil DNA glycosylase for class switch recombination. J. Biol. Chem. 282 (2007) 731-742
2. Bertele V., Assisi A., Di Muzio V., Renzo D., and Garattini S. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. Eur. J. Clin. Pharmacol. 63 (2007) 879-889
3. Bruneau J.-M., Yea C.M., Spinella-Jaegle S., Fudali C., Woodward K., Robson P.A., Sautes C., Westwood R., Kuo E.A., Williamson R.A., and Ruuth E. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem. J. 336 (1998) 299-303
4. Cherwinski H.M., Cohn R.G., Cheung P., Webster D.J., Xu Y.Z., Caulfield J.P., Yound J.M., Nakano G., and Ransom J.T. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275 (1995) 1043-1049
5. Fujieda S., Zhang K., and Saxon A. IL-4 plus CD40 monoclonal antibody induces human B cells gamma subclass-specific isotype switch: switching to gamma 1, gamma 3, gamma 4, but not gamma 2. J. Immunol. 155 (1995) 2318-2328
6. Herrmann M.L., Schleyerbach R., and Kirschbaum B.J. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 47 (2000) 273-289
7. Jones M.E. Pyrimidine nucleotide biosynthesis in animals: genes, enzymes and regulation of UMP biosynthesis. Ann. Rev. Biochem. 49 (1980) 253-279
8. Kawada K., Arimura A., Tsuri T., Fuji M., Komurasaki T., Yonezawa S., Kugimiya A., Haga N., Mitsumori S., Inagaki M., Nakatani T., Tamura Y., Takechi S., Taishi T., Kishino J., and Ohtani M. Total synthesis of Terprenin, a highly potent and novel immunoglobulin E antibody suppressant. Angew. Chem. Int. Educ. 37 (1998) 973-975
9. Manna S.K., and Aggarwal B.B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappaB activation and gene expression. J. Immunol. 162 (1999) 2095-2102
10. Min I.M., and Selsing E. Antibody class switch recombination: roles for switch sequences and mismatch repair proteins. Adv. Immunol. 87 (2005) 297-328
11. Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., and Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 (2000) 553-563
12. Muramatsu M., Nagaoka H., Shinkura R., Begum N.A., and Honjo T. Discovery of activation-induced cytidine deaminase, the engraver of antibody memory. Adv. Immunol. 94 (2007) 1-36
13. Ruckemann K., Fairbanks L.D., Carrey E.A., Hawrylowicz C.M., Richards D.F., Kirschbaum B., and Simmonds H.A. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T lymphocytes from healthy humans. J. Biol. Chem. 273 (1998) 21682-21691
14. Sekine H., Ferreira R.C., Pan-Hammarström Q., Graham R.R., Ziemba B., de Vries S.S., Liu J., Hippen K., Koeuth T., Ortmann W., Iwahori A., Elliott M.K., Offer S., Skon C., Du L., Novitzke J., Lee A.T., Zhao N., Tompkins J.D., Altshuler D., Gregersen P.K., Cunningham-Rundles C., Harris R.S., Her C., Nelson D.L., Hammarström L., Gilkeson G.S., and Behrens T.W. Role for Msh5 in the regulation of Ig class switch recombination. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7193-7198
15. Selsing E. Ig class switching: targeting the recombinational mechanism. Curr. Opin. Immunol. 18 (2006) 249-254
16. Siemasko K.F., Chong A.S.F., Williams J.W., Bremer E.G., and Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61 (1996) 635-642
17. Siemasko K., Chong A.S.-F., Jack H.-M., Gong H., Williams J.W., and Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads a block in IgG1 production. J. Immunol. 160 (1998) 1581-1588
18. Suissa S., Hudson M., and Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 54 (2006) 1435-1439
19. Williamson R.A., Yea C.M., Robson P.A., Curnock A.P., Gadher S., Hambleton A.B., Woodward K., Bruneau J.M., Hambleton P., Moss D., Thomson A., Spinella-Jaegle S., Morand P., Courtin O., Sautes C., Westwood R., Hercend T., Kuo E., and Ruuth E. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270 (1995) 22467-22472
20. Xu X., Shen J., Mall J.W., Myers J.A., Huang W., Blinder L., Saclarides T.J., Williams J.W., and Chong A.S.-F. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide. Biochem. Pharmacol. 58 (1999) 1405-1413